Chishui Xuanzhu

Xuanzhu Biopharmaceutical is a leading innovative biopharmaceutical company in China, operating as a subsidiary of Sihuan Pharmaceutical Holdings Group. The company's name is inspired by the Ming Dynasty medical classic "Chishui Xuanzhu," reflecting its commitment to medical excellence and innovation. Xuanzhu focuses on developing first-in-class and best-in-class therapies for oncology, metabolic diseases, and digestive disorders. It has successfully transitioned to a commercial-stage company with multiple approved products, including Anaprozole (a proton pump inhibitor) and Birociclib (a CDK4/6 inhibitor). The company maintains a robust pipeline of over 25 programs across various modalities, including small molecules, monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs), and it successfully listed on the Hong Kong Stock Exchange in October 2025.